Study of the incidence of monoclonal components in our area during 2018

2019 ◽  
Vol 493 ◽  
pp. S410
Author(s):  
A. Munoz ◽  
S. Pico ◽  
A. Criado ◽  
M. Bernal ◽  
A.D. Bernat ◽  
...  
Keyword(s):  
Monoclonal Components

Analysis of the Monoclonal Components in Systemic AL-Amyloidosis

Amyloidosis ◽  
1986 ◽  
pp. 509-515
Author(s):  
Jan Marrink ◽  
Theo Ockhuizen ◽  
Sven Janssen ◽  
Martin van Rijswijk ◽  
Enno Mandema
Keyword(s):  
Al Amyloidosis ◽  
Monoclonal Components

Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4191-4191 ◽  
Author(s):  
Helene Caillon ◽  
Michel Attal ◽  
Philippe Moreau ◽  
Thomas Dejoie
Keyword(s):  
Clinical Trial ◽  
Multiple Myeloma ◽  
Clinical Trials ◽  
Board Of Directors ◽  
Advisory Committees ◽  
Speed Of Response ◽  
Measurable Disease ◽  
Multiple Myelomas ◽  
The Impact ◽  
Monoclonal Components

Abstract Background: Detection and/or measurement of monoclonal components by serum protein electrophoresis (SPE) is essential for evaluation of response in multiple myeloma according to the International Myeloma Working Group (IMWG) criteria. Patient peak on SPE has a single presentation due to the extreme heterogeneity of monoclonal components based on isotype of immunoglobulin (Ig), charge, polymerization, viscosity, precipitation … Regarding the Ig isotype, distribution of myelomas has been known for a long time with about 55 % of IgG myelomas, 25 % of IgA myelomas, and 15% of light chain multiple myelomas (LCMM). Therefore differences in terms of various physical and chemical characteristics are observed according to isotype such as half-lives (IgG : 7-21 days ; IgA : 6 days ; only a few hours for light chains of Ig). Considering both differences about frequency and clearance according to Ig isotype, we addressed the question of the impact of isotype on the speed of response in multiple myeloma. Objective: The aim of this study was to assess if the different isotypes of monoclonal components involved in multiple myeloma have an impact on the velocity and the depth of response. Design and methods: Data from two recent clinical trials conducted by IFM were analysed. The first analysis was based on patients enrolled in the IFM DFCI 2009 clinical trial who benefited of each of the three MRD points planned in this trial (after induction and autograft for one arm, pre-maintenance and post-maintenance). Patients were categorized on the isotype of the monoclonal component involved : IgG, IgA or IgD intact immunoglobulin multiple myelomas (IIMM) with serum measurable disease according to IMWG criteria (i.e. serum monoclonal peak ≥ 10 g/L), LCMM, and IIMM without any serum measurable disease (i.e. serum monoclonal peak < 10 g/L).The percentage of patients who achieved at least a very good partial response (VGPR) was evaluated globally as well as for each category defined. The same analysis was carried out for the IFM 2013-04 clinical trial with one response assessment, after four induction cycles. Results: Concerning IFM DFCI 2009 trial, 398 patients evaluated on the three MRD points could be included in this analysis, divided into 185 and 213 in each arm of treatment. Within the total enrolment, two types of response kinetics could be distinguished : for IgA, IgD IIMM, IIMM without serum measurable disease and LCMM, the gain of response between post-induction +/- autograft and post-maintenance is on average 11,1 points (6,7 - 15) when IgG myelomas presented a difference of VGPR percentage of 27,9 points. The same observation could be made for each arm of treatment : 16,6 and 5,8 points of VGPR percentage gained in each arm for the "faster response" group as defined previously, whereas 33,3 and 23,3 points were gained for IgG myelomas. Apart from this difference of kinetics, we notably observed that IgG myelomas never reached VGPR rates obtained with other isotype myelomas. About IFM 2013-04 trial, 264 patients could be evaluated in our analysis after four cycles of VTD (131) or VCD (133) for induction. 98,0% of IgA myelomas achieved at least VGPR after induction (96,3% for VTD arm and 100% for VCD arm) whereas only 50,6% for IgG myelomas (57,3% and 43,2%) and 68,3% for LCMM (46,7% for VTD arm and 80,8 for VCD arm). Conclusion: This study shows that time of evaluation is a key factor regarding the different speed of response for each isotype of Ig. IgA myelomas and LCMM have a faster response than IgG myelomas. IgG myelomas have a lower biochemical response than other isotype myelomas. Consequently, for an accurate interpretation of data in clinical trials, patients should be equally distributed in each arm of treatment according to their isotype. Ideally, to be compared, clinical trials should always have the same isotype distribution, especially when an early evaluation is performed such as after induction. Disclosures Attal: jansen: Honoraria; celgene: Membership on an entity's Board of Directors or advisory committees. Moreau:Celgene, Janssen, Takeda, Novartis, Amgen: Membership on an entity's Board of Directors or advisory committees.

A new approach for rapid detection and typing of serum monoclonal components

2000 ◽  
Vol 302 (1-2) ◽  
pp. 105-124
Author(s):  
P. Cacoub ◽  
A.C. Camproux ◽  
J.M. Thiolières ◽  
U. Assogba ◽  
P. Hausfater ◽  
...  
Keyword(s):  
Rapid Detection ◽  
New Approach ◽  
Monoclonal Components

Frequent discordance of the light-chain isotypes expressed by serum monoclonal components and leukaemic B-cells

2002 ◽  
Vol 24 (3) ◽  
pp. 151-154 ◽  
Author(s):  
D. Brohée ◽  
P. Cauchie ◽  
L. Delval ◽  
D. Govaerts ◽  
P. Nève ◽  
...  
Keyword(s):  
B Cells ◽  
Light Chain ◽  
Monoclonal Components

Occurrence of monoclonal components in general practice: Clinical implications

2009 ◽  
Vol 48 (4) ◽  
pp. 192-195 ◽  
Author(s):  
F. Aguzzi ◽  
M. R. Bergami ◽  
C. Gasparro ◽  
V. Bellotti ◽  
G. Merlini
Keyword(s):  
General Practice ◽  
Clinical Implications ◽  
Monoclonal Components

Serum double monoclonal components and hematological malignancies: Only a casual association? Review of 34 cases

2012 ◽  
Vol 36 (10) ◽  
pp. 1274-1277 ◽  
Author(s):  
Salvatore Guastafierro ◽  
Maria Giovanna Ferrara ◽  
Antonello Sica ◽  
Rita Rosaria Parascandola ◽  
Sara Santangelo ◽  
...  
Keyword(s):  
Hematological Malignancies ◽  
Monoclonal Components

Clinical significance of serum triple monoclonal components: A report of 6 cases and a review of the literature

2014 ◽  
Vol 38 (2) ◽  
pp. 166-169 ◽  
Author(s):  
Salvatore Guastafierro ◽  
Antonello Sica ◽  
Rita Rosaria Parascandola ◽  
Maria Giovanna Ferrara ◽  
Anna Di Martino ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Review Of The Literature ◽  
Monoclonal Components

Use of immunoglobulin heavy-chain and light-chain measurements in a multicenter trial to investigate monoclonal components: I. Detection

1991 ◽  
Vol 37 (11) ◽  
pp. 1917-1921 ◽  
Author(s):  
R G Jones ◽  
F Aguzzi ◽  
J Bienvenu ◽  
P Bianchi ◽  
C Gasparro ◽  
...  
Keyword(s):  
Light Chain ◽  
Quantitative Methods ◽  
Multicenter Trial ◽  
Light Chains ◽  
Free Light Chains ◽  
Quantitative Measurements ◽  
Combined Use ◽  
Monoclonal Immunoglobulins ◽  
Immunofixation Electrophoresis ◽  
Monoclonal Components

Abstract We assessed the combined use of serum protein electrophoresis (SPE) and nephelometric measurement of immunoglobulin heavy- and light-chain components for detecting serum monoclonal immunoglobulins (monoclonal components, MC) in 4788 unselected samples from 4173 patients. MC were detected in 514 samples from 390 patients. In 356 these were detected by SPE; the other 34 had a normal SPE pattern but an abnormal kappa:lambda light-chain ratio (KLR). Only 208 of the 356 (58%) samples with bands by SPE had abnormal KLRs. Samples with MC concentrations greater than 5 g/L had a higher proportion of abnormal KLRs (75%) than those with concentrations less than 5 g/L (42%). The KLR was abnormal in 13% of samples in which no MC were visible by SPE or immunofixation electrophoresis (IFE). Compared with quantitative measurements of immunoglobulin heavy and light chains, high-quality SPE remains the method of choice for the detection of MC. Quantitative methods, however, are able to detect additional MC, especially those containing free light chains, and in the absence of SPE and IFE will detect about 75% of MC present at greater than 5 g/L.

Sign in / Sign up

Export Citation Format

Share Document